ストックスクリーナーアプリを入手
4.62
0.00%
0.00
前日終値:
$4.62
開ける：
$4.64
24時間の取引高:
595.84K
Relative Volume:
0.54
時価総額：
$248.86M
収益：
$1.02B
当期純損益:
$-757.20M
株価収益率:
-0.313
EPS:
-14.76
ネットキャッシュフロー:
$-257.90M
1週間 パフォーマンス:
+8.45%
1か月 パフォーマンス:
-20.21%
6か月 パフォーマンス:
-49.45%
1年 パフォーマンス:
+143.16%
1日の値動き範囲:
$4.49
$4.6895
1週間の範囲:
$4.1301
$4.6895
52週間の値動き範囲:
$1.8201
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
名前
Emergent Biosolutions Inc
セクター
電話
240-631-3200
住所
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
4.62 | 248.86M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
| 2024-03-07 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Underweight |
| 2023-08-29 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-04-10 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-10 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-04-29 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-11-08 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-05-05 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 開始されました | The Benchmark Company | Buy |
| 2021-02-24 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-07-31 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
| 2019-09-04 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | アップグレード | Goldman | Neutral → Buy |
| 2018-08-03 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-06-13 | 開始されました | Argus | Buy |
| 2018-04-25 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2018-01-16 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | Singular Research | Buy |
| 2016-04-15 | 開始されました | Chardan Capital Markets | Buy |
| 2016-03-28 | 開始されました | Singular Research | Buy |
| 2016-02-19 | 開始されました | Wells Fargo | Outperform |
| 2014-05-15 | 開始されました | Summer Street Research | Buy |
| 2011-05-31 | 繰り返されました | WBB Securities | Strong Buy |
| 2011-01-10 | 繰り返されました | Wedbush | Outperform |
| 2010-11-05 | 繰り返されました | Wedbush | Outperform |
| 2010-08-18 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 繰り返されました | Caris & Company | Buy |
すべてを表示
Emergent Biosolutions Inc (EBS) 最新ニュース
Lobbying Update: $920,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Emergent BioSolutions launches stock repurchase program - MSN
Mile Marker Continues New Business Success With Growth-Oriented Brands - Yahoo Finance
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS - Business Wire
Emergent BioSolutions sets $50 million stock buyback plan By Investing.com - Investing.com South Africa
Emergent BioSolutions Authorizes $50 Million Stock Buyback Program - MarketScreener
Emergent BioSolutions Announces Repurchase Of Up To $50 Mln Stock, Pre-market Stock Up - Nasdaq
Emergent BioSolutions sets $50 million stock buyback plan - Investing.com
$50M Stock Buyback: Emergent BioSolutions Signals Strong Confidence in Turnaround Plan - Stock Titan
Q1 Earnings Estimate for EBS Issued By HC Wainwright - MarketBeat
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (NYSE:EBS) - Seeking Alpha
SEC Form DEFA14A filed by Emergent BioSolutions Inc. - Quantisnow
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts - Benzinga
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet - simplywall.st
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - The Manila Times
Just Awarded: Emergent BioSolutions Grants Major 72,882 Share Package to Strategic New Hire - Stock Titan
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues - Seeking Alpha
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - The Manila Times
Breakthrough: New High-Dose Naloxone Spray Gets Health Canada Green Light as Overdose Crisis Persists - StockTitan
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions - Medical Dialogues
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - citybiz
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc. - Equity Bulls
Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com South Africa
Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International - Marketscreener.com
Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com India
Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International - Marketscreener.com
Emergent BioSolutions Strategic Win: $36.5M Facility Sale While Securing Future Production Rights - StockTitan
Emergent BioSolutions secures $27 million in MCM orders By Investing.com - Investing.com Australia
Emergent BioSolutions secures $27 million in MCM orders - Investing.com
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - The Manila Times
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International - EIN News
Syngene Acquires First US Manufacturing Facility - Contract Pharma
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Emergent BioSolutions to invest in Rocketvax for vaccine developments - MSN
Emergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5M - MSN
Emergent signs financial investment agreement with Swiss Rockets - Yahoo
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - The Manila Times
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by ... - The Bakersfield Californian
First OTC Narcan Program Targets High-Risk Construction Workers to Combat Overdose Crisis - StockTitan
Emergent BioSolutions director Zoon sells $57,300 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock - Investing.com India
Emergent BioSolutions director Zoon sells $57,300 in stock - Investing.com
Emergent Biosolutions Inc (EBS) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
0.80%
大文字化:
|
ボリューム (24 時間):